AbCellera raises $105M to fund antibody drug development

By The Science Advisory Board staff writers

May 27, 2020 -- Artificial intelligence-powered biotech and drug discovery platform AbCellera has closed a $105 million series B financing round to expand its capacity and more.

The funds will be used to accelerate the development of biologics and to invest in technologies that complement and extend its antibody discovery platform. Specifically, AbCellera will use the funds to create and aggregate novel tools to propel the development of new biological modalities, from monoclonal, multispecific, and single-domain antibodies, to bioconjugates, gene-encoded biologics, and cell therapies.

The money also will be used to expand AbCellera's workforce, open a new research facility in 2021, and build a manufacturing facility that will produce biologics for clinical testing.

Current investor DCVC Bio and OrbiMed led the financing. Other investors include Viking Global Investors, Peter Thiel, Founders Fund, Eli Lilly and Company, the University of Minnesota, and Presight Capital.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here